: From startup to scale-up: Quentin Colmant on scaling an insurance business in a highly regulated industry

scale-up
co:lab podcast logo

How do you build a company that can survive regulation, crises, and hypergrowth - all at the same time?

In this co:lab episode, we welcome Quentin Colmant, CEO and co-founder of Qover, one of Europe’s leading embedded insurance platforms.

From his early career at Allianz to founding Qover in 2016, Quentin shares an honest and unfiltered look at what it really takes to scale a tech company in a highly regulated industry. Together, we explore the strategic decisions behind Qover’s growth to 150 employees today, partnerships with global brands like Tesla, Revolut and Mastercard, and the realities of navigating Brexit, COVID, and volatile capital markets and changes in policies.

blue dots of co:lab

The conversation touches on:

  • Why resilience is the most critical trait for entrepreneurs
  • The trade-offs betweenfocus and diversification when scaling
  • Raising capital:VCs vs corporate investors
  • Building trust with large international partners
  • HowAI is transforming insurance operations
  • Why work-life balance is often a myth for founders, and how to cope with that reality

A must-listen episode for founders, executives and anyone interested in building beyond the next funding round.

other podcasts

photo of Nico Huybrechts during co:lab podcast
Season 2 Episode 8
Scaling Datashift: Nico Huybrechts on Growth, Governance and AI 
In the final episode of this co:lab season, we sit down with Nico Huybrechts, founder and CEO of Datashift. Ten years ago, Datashift started at the kitchen table. Today, it is a multidisciplinary data & AI consultancy operating across borders. But this conversation goes beyond numbers.
podcast colab ep.7 - Leen Limbourg
Season 2 Episode 7
How life sciences innovation survives uncertainty with investor Leen Limbourg
In this episode of co:lab, we speak with Leen Limbourg, medical doctor, investor and experienced board member, about the realities of building and funding life sciences companies in today’s challenging environment.